Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

GSK1120212 Rollover Study

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: GSK1120212
Drug: Docetaxel + GSK1120212
Drug: Erlotinib + GSK1120212
Drug: Pemetrexed + GSK1120212
Drug: Carboplatin + GSK1120212
Drug: Nab-paclitaxel + GSK1120212
Drug: Gemcitabine + GSK1120212
Drug: Everolimus + GSK1120212

First Posted Date: 2011-06-20

Last Posted Date: 2019-02-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 159

Registration Number: NCT01376310

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: KRP203
Drug: Placebo matching KRP203

First Posted Date: 2011-06-17

Last Posted Date: 2020-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01375179

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Phase 3

Completed

Conditions: Cushing's Disease

Interventions: Drug: pasireotide LAR
Drug: SOM230 LAR 10 mg
Drug: SOM230 LAR 30 mg

First Posted Date: 2011-06-16

Last Posted Date: 2018-05-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT01374906

Locations: 🇺🇸
University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States
🇺🇸
University of Pennsylvania - Clinical Studies Unit Unniv SC, Philadelphia, Pennsylvania, United States
🇺🇸
Emory University School of Medicine/Winship Cancer Institute G2304 - C2301, Atlanta, Georgia, United States

and more 10 locations

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Phase 2

Terminated

Conditions: Islet Cell Tumor

Interventions: Drug: Everolimus
Drug: Pasireotide LAR

First Posted Date: 2011-06-16

Last Posted Date: 2016-12-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 160

Registration Number: NCT01374451

Locations: 🇺🇸
Dana Farber Cancer Institute SC-2, Boston, Massachusetts, United States
🇺🇸
Montefiore Medical Center MMC, Bronx, New York, United States
🇺🇸
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, United States

and more 2 locations

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Phase 2

Terminated

Conditions: Hypertension

Interventions: Drug: LFF269
Drug: Eplerenone
Drug: Placebo

First Posted Date: 2011-06-14

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT01373086

Locations: 🇺🇸
Comprehensive Phase I, Fort Myers, Florida, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸
Internal Medicine Physicians, Omaha, Nebraska, United States

and more 8 locations

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Phase 4

Terminated

Conditions: Hypertension
Stage 2 Hypertension
Diabetes

Interventions: Drug: Valturna
Drug: Placebo of Valturna Tablet
Drug: Chlorthalidone
Drug: Amlodipine
Drug: Placebo Capsule

First Posted Date: 2011-06-08

Last Posted Date: 2013-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 975

Registration Number: NCT01368536

Locations: 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Phase 4

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: nilotinib

First Posted Date: 2011-06-08

Last Posted Date: 2016-11-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT01368523

Locations: 🇵🇱
Novartis Investigative Site, Warsaw, Poland

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Phase 3

Completed

Conditions: Moderate to Severe Plaque-type Psoriasis

Interventions: Drug: secukinumab 150 mg
Drug: placebo to secukinumab 150 mg

First Posted Date: 2011-06-03

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 738

Registration Number: NCT01365455

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Phase 2

Terminated

Conditions: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Interventions: Drug: Everolimus (RAD001)

First Posted Date: 2011-06-03

Last Posted Date: 2016-05-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT01365468

Locations: 🇮🇱
Novartis Investigative Site, Tel-Hashomer, Israel

Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age

Phase 3

Completed

Conditions: Hypertension
Chronic Kidney Disease

Interventions: Drug: Valsartan
Drug: amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2011-06-03

Last Posted Date: 2016-07-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT01365481

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy